Trial Profile
A phase-III, comparative, randomized, multicenter clinical trial of Molnupiravir in mild Covid-19 patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Feb 2022
Price :
$35
*
At a glance
- Drugs Molnupiravir (Primary) ; Antivirals
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors Hetero Biopharma
- 24 Feb 2022 New trial record
- 19 Feb 2022 According a Hetero Biopharma media release, result from this study presented as an Oral Abstract at the Conference on Retroviruses and Opportunistic Infections (CROI), 2022.
- 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections